Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.

Lancet Oncol. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5. Epub 2019 Jul 19. Erratum in: Lancet Oncol. 2019 Oct;20(10):e559.

PMID:
31331701
2.

Distal extremities soft tissue sarcomas: Are they so different from other limb localizations?

Mattei JC, Brouste V, Terrier P, Bonvalot S, Lecesne A, Stoeckle E, Italiano A, Ranchere-Vince D, Meeus P, Laé M, Rosset P, Rochwerger A, Coindre JM, Salas S.

J Surg Oncol. 2019 Mar;119(4):479-488. doi: 10.1002/jso.25359. Epub 2019 Jan 4.

PMID:
30609044
3.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.

Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18.

PMID:
30578023
4.

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).

Chaigneau L, Patrikidou A, Ray-Coquard I, Valentin T, Linassier C, Bay JO, Moureau Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Laigre M, Guillemet C, Salas S, Hugli A, Domont J, Sunyach MP, Lecesne A, Blay JY, Nerich V, Isambert N.

Oncologist. 2018 Aug;23(8):948-955. doi: 10.1634/theoncologist.2017-0136. Epub 2018 Jun 22.

5.

Interventional radiology: Role in the treatment of sarcomas.

de Baere T, Tselikas L, Gravel G, Hakime A, Deschamps F, Honoré C, Mir O, Lecesne A.

Eur J Cancer. 2018 May;94:148-155. doi: 10.1016/j.ejca.2018.02.017. Epub 2018 Mar 20. Review.

PMID:
29567631
6.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

7.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

8.

Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?

Honoré C, Atallah V, Mir O, Orbach D, Ferron G, LePéchoux C, Delhorme JB, Philippe-Chomette P, Sarnacki S, Msika S, Terrier P, Glehen O, Martelli H, Minard-Colin V, Bertucci F, Blay JY, Bonvalot S, Elias D, LeCesne A, Sargos P; French Network for Rare Peritoneal Malignancies (RENAPE), French Pediatric Cancer Society (SFCE), French Reference Network in Sarcoma Pathology (RRePS) French Sarcoma Clinical Network (NETSARC).

PLoS One. 2017 Feb 24;12(2):e0171639. doi: 10.1371/journal.pone.0171639. eCollection 2017.

9.

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P.

Clin Sarcoma Res. 2016 Sep 14;6(1):15. doi: 10.1186/s13569-016-0056-0. eCollection 2016. Review.

10.

Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

Toulmonde M, Bonvalot S, Ray-Coquard I, Stoeckle E, Riou O, Isambert N, Bompas E, Penel N, Delcambre-Lair C, Saada E, Lecesne A, Le Péchoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchère-Vince D, Neuville A, Italiano A; French Sarcoma Group.

Ann Oncol. 2014 Mar;25(3):730-4. doi: 10.1093/annonc/mdt576. Epub 2014 Feb 3.

11.

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group.

Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, Ray-Coquard I, Chabaud S, Penel N, Berge Y, Dômont J, Italiano A, Duffaud F, Cadore AC, Polivka V, Blay JY.

Br J Cancer. 2013 Aug 20;109(4):909-14. doi: 10.1038/bjc.2013.442. Epub 2013 Aug 6.

12.

Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 function.

Muret J, Hasmim M, Stasik I, Jalil A, Mallavialle A, Nanbakhsh A, Lacroix L, Billot K, Baud V, Thiery J, Vielh P, Terrier P, Wiels J, Vassilev L, Lecesne A, Bonvalot S, Chouaib S.

PLoS One. 2012;7(6):e38808. doi: 10.1371/journal.pone.0038808. Epub 2012 Jun 18.

13.

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L.

Nat Med. 2011 Jun;17(6):700-7. doi: 10.1038/nm.2366. Epub 2011 May 8.

PMID:
21552268
14.

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial.

Assi H, Missenard G, Terrier P, Le Pechoux C, Bonvalot S, Vanel D, Meric JB, Tursz T, Lecesne A.

Curr Oncol. 2010 Nov;17(6):23-31.

15.

Cyclophosphamide induces differentiation of Th17 cells in cancer patients.

Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L.

Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9.

16.

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Séronie-Vivien S, LeCesne A, Vassal G; Innovative Therapies with Children with Cancer European consortium.

Clin Cancer Res. 2008 Nov 1;14(21):7102-9. doi: 10.1158/1078-0432.CCR-08-0950.

17.

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L.

J Exp Med. 2005 Oct 17;202(8):1075-85.

18.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I.

Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34.

PMID:
15451219
19.

[55 year-old male presenting with an abdominal mass].

Benoist S, Lecesne A.

J Chir (Paris). 2002 Dec;139(6):332-8. French. No abstract available.

PMID:
12538953
20.

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas.

Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, LeCesne A, Chauvin F, Blay JY; ELYPSE Study Group.

Br J Cancer. 2001 Sep 14;85(6):816-22.

21.

Recurrence of a primary malignant giant cell tumour of bone 14 years after initial surgery.

Merad M, Mesurolle B, Guinebretière JM, Lecesne A, Missenard G, Vanel D.

Eur Radiol. 2001;11(8):1483-6.

PMID:
11519561
22.

Primary sarcomas of the central nervous system.

Merimsky O, Lepechoux C, Terrier P, Vanel D, Delord JP, LeCesne A.

Oncology. 2000 Apr;58(3):210-4.

PMID:
10765122
23.

[The Cleopatra project].

Lotz JP, Lecesne A, Trillet-Lenoir V.

Rev Pneumol Clin. 1999 Sep;55(4):234-5. French. No abstract available.

PMID:
10573755
24.

[Primary cutaneous leiomyosarcoma: 32 cases].

Auroy S, Contesso G, Spatz A, Genin J, Margulis A, Lecesne A, Avril MF.

Ann Dermatol Venereol. 1999 Mar;126(3):235-42. French.

25.

Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases.

Mairal A, Terrier P, Chibon F, Sastre X, Lecesne A, Aurias A.

Cancer Genet Cytogenet. 1999 Jun;111(2):134-8.

PMID:
10347550
26.

Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.

Belli L, LeChevalier T, Gottfried M, Adams D, Ruffie P, LeCesne A, Tete L, Pellae-Cosset B.

Semin Oncol. 1995 Dec;22(6 Suppl 15):29-33.

PMID:
8643967
27.

Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.

Angevin E, Valteau-Couanet D, Farace F, Dietrich PY, Lecesne A, Triebel F, Escudier B.

J Immunother Emphasis Tumor Immunol. 1995 Oct;18(3):188-95.

PMID:
8770775
28.

Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.

Elias D, Farace F, Triebel F, Hattchouel JM, Pignon JP, Lecesne A, Rougier P, Lasser P, Duvillard P, Escudier B.

J Am Coll Surg. 1995 Oct;181(4):303-10.

PMID:
7551323

Supplemental Content

Loading ...
Support Center